Natera, Inc. ($NTRA) Stock Forecast: Down 5.5% Today

What is Natera, Inc.?

Natera Inc. (NTRA) is a diagnostic and research company known for its molecular residual disease test, Signatera. The company has been making strides in the healthcare industry with its innovative solutions and has garnered attention from both institutional investors and analysts.

Why is Natera, Inc. going down?

NTRA stock is down 5.5% on Apr 9, 2026 14:11

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes

Matthew Rabinowitz, Executive Chairman of Natera (NASDAQ: NTRA), exercised stock options to acquire 58,292 shares at $9.59 each and subsequently had 27,610 shares withheld at $204.87 for tax obligations. Following these transactions, Rabinowitz directly holds 2,383,162 shares and indirectly holds 5,000 shares through his spouse. The filing also details key figures like exercise price, tax-withholding price, and his holdings after the transactions.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-69aa6881ce05.html

NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.

https://intellectia.ai/en/stock/NTRA/financials

Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller

Billionaire Stan Druckenmiller's Duquesne Capital holds a significant stake in Natera, Inc. (NTRA), increasing its position in the company which is recognized for its molecular residual disease test, Signatera. Natera's recent achievement of positive cash inflow in 2025 has shifted the narrative among institutional investors, mitigating concerns about cash burn and potential dilution risks. The article highlights the strong growth of Signatera and Natera's growing integration into clinical guidelines as key drivers for its upside potential.

https://www.insidermonkey.com/blog/natera-inc-ntra-upside-potential-pulls-billionaire-stan-druckenmiller-1733871/?amp=1

Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300

Citi has reiterated its Buy rating for Natera (NTRA.US) and maintained a target price of $300. This continued endorsement suggests the firm sees strong potential for the company's performance, indicating a positive outlook on its valuation and business prospects.

https://www.moomoo.com/news/post/67968518/citi-maintains-natera-ntraus-with-buy-rating-maintains-target-price

Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating

Citi has placed Natera (NTRA) on a "90-day catalyst watch" and reaffirmed its Buy rating with a $300 price target, anticipating strong financial momentum despite a recent stock pullback. Natera, a diagnostic and research company, shows robust revenue growth and a strong balance sheet but faces challenges in profitability and has high institutional ownership alongside insider selling. The company's performance, particularly upcoming earnings, will be key to its future trajectory, requiring investor vigilance regarding valuation and insider activity.

https://www.gurufocus.com/news/8777278/natera-ntra-gets-90day-catalyst-watch-from-citi-and-maintains-buy-rating?mobile=true

Trending Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 7.1% Today

lululemon athletica inc. ($LULU) Stock Forecast: Up 5.4% Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 5.1% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.7% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Down 5.5% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.4% Today

Snowflake Inc ($SNOW) Stock Forecast: Down 11.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.1% Today

Gap Inc. ($GAP) Stock Forecast: Up 5.1% Today

PVH Corp. ($PVH) Stock Forecast: Up 5.0% Today

Natera, Inc. Price History

09.03.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

31.02.2026 - NTRA Stock was up 5.1%

• Increased positions by Dakota Wealth Management and DAVENPORT & Co LLC suggest growing institutional interest, which has contributed to the bullish movement.
• Although there is strong institutional ownership, insider selling by CEO Steven Leonard Chapman and others may have caused initial uncertainty among investors.
• Natera's positive Q4 earnings report, surpassing expectations, likely boosted investor confidence and supported the bullish movement.
• Despite being considered undervalued by some estimates, recent share price weakness may have prompted profit-taking and a temporary decrease in the stock price.

31.02.2026 - NTRA Stock was up 6.5%

• Zevenbergen Capital Investments LLC decreased its stake in Natera, Inc. by 18%, while other institutional investors like Dakota Wealth Management and DAVENPORT & Co LLC have shown increased interest, reflecting diverse sentiments within the market.
• The positive development concerning Natera's Signatera™ MRD test aiding older women with breast cancer to avoid surgery likely contributed to the bullish movement, highlighting the company's advanced and impactful technology.
• Despite recent insider selling, including by the CEO, robust quarterly results surpassing expectations have upheld analyst confidence in Natera, with a "Moderate Buy" consensus and an average price target of $253.47, potentially fueling investor confidence and propelling the stock price higher.
• The decline in Natera's shares on March 30 may have been a temporary setback amidst generally positive sentiment, with Wall Street analysts forecasting a substantial upside and maintaining an "Outperform" recommendation, signaling a possible buying opportunity for investors.

01.03.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera Inc. (NTRA) today could be attributed to the positive results from the Signatera molecular residual disease (MRD) test, particularly in identifying breast cancer patients who may avoid surgery, boosting investor confidence in the company's innovative technology.
• Despite the recent share sell-off by Zevenbergen Capital Investments LLC, the overall market sentiment remains positive, with increased interest from other institutional investors and strong quarterly results beating expectations, supporting the stock's upward momentum.
• The study showcasing the efficacy of Signatera in guiding treatment decisions for older women with early-stage breast cancer likely contributed to the stock's bullish movement, as it highlights the potential market expansion and adoption of Natera's testing solutions.

04.02.2026 - NTRA Stock was up 5.8%

• The Chief Legal Officer of Natera receiving a significant number of restricted stock units (RSUs) aligns his incentives with the company's performance, indicating confidence in the company's future prospects.
• Mentioned company's reiteration of a Buy rating and positive revenue forecast for 2026 boosted investor confidence, leading to an increase in Natera's stock price.
• Despite a price target cut for Natera by a specific investment firm, other analysts maintaining Buy ratings and positive outlooks on the company's earnings and revenue growth contributed to the bullish market movement.
• The overall positive sentiment towards Natera, driven by strong Q4 results and optimistic forecasts, outweighed concerns over recent market volatility and inflation, leading to the stock's upward trajectory.

06.01.2026 - NTRA Stock was down 6.2%

• Natera's President and Chief Business Officer selling a substantial amount of company stock to cover tax obligations might have signaled a lack of confidence in the company's short-term performance, contributing to the bearish movement.
• The sale of Natera stock by the President of Clinical Diagnostics, following a period of stock volatility and concerns about overvaluation, could have added to the negative sentiment among investors.
• The mid-day trading price drop of 7.82% on February 4th could be a result of a combination of insider selling, perceived overvaluation, and overall market volatility affecting Natera's stock price.
• The AI-driven trading systems highlighting weak near-term sentiment despite long-term strength might have influenced traders to react to the short-term risks associated with Natera, leading to the bearish movement in the stock price.

05.01.2026 - NTRA Stock was down 5.5%

• The bearish market movement of NTRA stock could be linked to insider selling activities by the company's top executives, such as President Moshkevich and President Fesko, leading to concerns among investors about the company's future prospects.
• Despite strong preliminary Q4 2025 results and advancements in diagnostic technologies, the stock saw a notable decline possibly because of profit-taking by insiders and investor reactions to perceived stock overvaluation.
• The submission of Signatera CDx PMA to the FDA for detecting molecular residual disease in bladder cancer patients could act as a positive long-term catalyst for Natera. However, short-term market sentiment appears influenced more by insider selling and valuation concerns.
• AI-driven trading systems highlighting weak near-term sentiment and a significant risk-reward setup targeting an 11.5% gain might have also contributed to increased volatility and downward pressure on NTRA stock.

18.01.2026 - NTRA Stock was up 5.5%

• Anticipation and positive sentiment among investors were fueled by Natera's announcement of the upcoming release of its fourth quarter and full-year results.
• Institutional investors, such as Zweig DiMenna Associates LLC, increased their stake, indicating confidence in Natera's future performance and contributing to the bullish trend.
• Despite some company insiders selling off shares, the market remains optimistic about Natera's growth potential, evident from the stock's positive movement.
• An average price target of $249.20 alongside analysts' "Moderate Buy" consensus rating bode well for Natera, reinforcing the bullish market sentiment.

12.02.2026 - NTRA Stock was down 5.3%

• The downward movement in NTRA stock recently could be linked to a series of insider selling actions by senior executives, such as the President, CFO, and CEO, causing apprehension among investors regarding the company's future trajectory.
• Despite the positive performance in Q4 earnings, the pessimistic yearly EPS forecast and insider selling transactions might have outweighed the favorable revenue numbers, resulting in reduced investor trust and a subsequent dip in the stock value.
• The recurrent trend of insider sales, even after outperforming analyst estimates, may imply a disconnect between key individuals within the company and market sentiments, fostering uncertainty and contributing to the current bearish sentiment in NTRA stock.

27.02.2026 - NTRA Stock was down 5.1%

• Despite the launch of the Zenith Genomic Assay, Natera (NTRA) witnessed a bearish movement in the market.
• The stock's decline could be related to perceptions of the company being overvalued based on a Price-to-Sales ratio comparison, despite being considered undervalued in a Discounted Cash Flow analysis.
• Insider selling by the CFO and CEO, along with the company's lack of profitability and negative net margin, may have increased investor apprehensions and influenced the market's bearish trend.
• Investors are possibly reevaluating their positions in Natera (NTRA) after the recent downturn, despite the company's solid historical performance and favorable outlook from financial analysts.

27.01.2026 - NTRA Stock was down 6.6%

• Notable insider selling of Natera shares could be influencing the bearish trend, possibly indicating reservations or a lack of confidence among company insiders.
• Despite promising results from Phase 2 trials related to head and neck cancer, the market response may have been negative due to concerns surrounding the upcoming earnings announcement, with analysts predicting a per-share loss.
• The expectation of an unfavorable EPS in the forthcoming earnings report may have outshone the positive trial outcomes, contributing to a pessimistic outlook among investors.
• The divergence between the favorable trial results and the projected earnings loss could be causing uncertainty and fluctuations in Natera's stock value, resulting in the observed bearish sentiment in the market.

11.02.2026 - NTRA Stock was down 5.1%

• Quantbot Technologies LP and Victory Capital Management Inc. both made significant moves in their stakes with Natera, indicating conflicting sentiments among institutional investors.
• The increased insider selling by CEO and CFO, despite strong earnings and revenue beats, may have raised concerns among investors about the company's future performance.
• The mixed valuation assessments, with one model suggesting undervaluation and another pointing to an expensive sales multiple, could have contributed to the bearish market movement as investors reevaluate Natera's true worth.
• Overall, the combination of insider selling, conflicting institutional investor actions, and valuation uncertainties likely led to the bearish movement in Natera's stock today.